{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:52:54Z","timestamp":1789404774509,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,17]],"date-time":"2016-01-17T00:00:00Z","timestamp":1452988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ophtha.2016.01.019","type":"journal-article","created":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T22:26:22Z","timestamp":1455315982000},"page":"965-973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1016","volume":"123","clinical-trial-number":[{"clinical-trial-number":"nct01749904","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert N.","family":"Weinreb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baldo","family":"Scassellati Sforzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-1191","authenticated-orcid":false,"given":"Jason","family":"Vittitow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Liebmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.01.019_bib1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","article-title":"Primary open-angle glaucoma","volume":"363","author":"Weinreb","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2016.01.019_bib2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2016.01.019_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","article-title":"An assessment of the health and economic burdens of glaucoma","volume":"152","author":"Varma","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib4","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1001\/archopht.1980.01020041015002","article-title":"Biostatistical analysis of the collaborative glaucoma study, I: summary report of the risk factors for glaucomatous visual-field defects","volume":"98","author":"Armaly","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The ocular hypertension treatment study: a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib6","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib8","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","article-title":"Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery","volume":"108","author":"Lichter","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.01.019_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","article-title":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures","volume":"126","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib11","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomized, multicentre, placebo-controlled trial","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2016.01.019_bib12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2147\/OPTH.S63760","article-title":"Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs","volume":"8","author":"Schmier","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.exer.2011.03.001","article-title":"Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2\u03b1 agonist, in preclinical models","volume":"93","author":"Krauss","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2016.01.019_bib14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","article-title":"A\u00a0randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study","volume":"99","author":"Weinreb","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib15","first-page":"2214","article-title":"Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in\u00a0vitro","volume":"38","author":"Lindsey","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.01.019_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00055735-200004000-00008","article-title":"The mechanism of action of prostaglandins in uveoscleral outflow","volume":"11","author":"Schachtschabel","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archopht.119.8.1165","article-title":"Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment","volume":"119","author":"Gaton","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib18","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1167\/iovs.02-1281","article-title":"Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide","volume":"44","author":"Richter","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.01.019_bib19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0022-3565(25)11469-9","article-title":"Nitrovasodilators as a new class of ocular hypotensive agents","volume":"260","author":"Nathanson","year":"1992","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ophtha.2016.01.019_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/exer.1994.1199","article-title":"Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys","volume":"58","author":"Schuman","year":"1994","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2016.01.019_bib21","first-page":"2515","article-title":"Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide","volume":"35","author":"Wiederholt","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.01.019_bib22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00417-002-0559-7","article-title":"Nitric oxide\/guanylate cyclase pathways and flow in anterior segment perfusion","volume":"240","author":"Schneemann","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1076\/ceyr.26.2.119.14511","article-title":"Nitric oxide and cyclic GMP enhance aqueous humor outflow facility in rabbits","volume":"26","author":"Kotikoski","year":"2003","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2016.01.019_bib24","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1167\/iovs.12-11491","article-title":"Effect of nitric oxide on anterior segment physiology in monkeys","volume":"54","author":"Heyne","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.01.019_bib25","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1167\/iovs.14-14515","article-title":"Nitric oxide (NO): an emerging target for the treatment of glaucoma","volume":"55","author":"Cavet","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.01.019_bib26","doi-asserted-by":"crossref","first-page":"C205","DOI":"10.1152\/ajpcell.00347.2014","article-title":"Role of nitric oxide in murine conventional outflow physiology","volume":"309","author":"Chang","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib27","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1167\/iovs.15-16564","article-title":"Aqueous humor outflow physiology in NOS3 knockout mice","volume":"56","author":"Lei","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.01.019_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archophthalmol.2009.384","article-title":"Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study","volume":"128","author":"Higginbotham","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib29","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(14)62347-3","article-title":"Glaucoma treatment: by the highest level of evidence","volume":"385","author":"Heijl","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2016.01.019_bib30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0002-9394(14)72725-4","article-title":"The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study: 7. Results","volume":"120","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib31","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S0161-6420(94)31120-1","article-title":"Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma","volume":"101","author":"Migdal","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.01.019_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0002-9394(14)76896-5","article-title":"Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma","volume":"111","author":"Mao","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib33","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bjo.69.11.827","article-title":"Progression of field loss after trabeculectomy: a five-year follow-up","volume":"69","author":"Kidd","year":"1985","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib34","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archopht.126.8.1030","article-title":"Canadian Glaucoma Study: 2. Risk Factors for the Progression of Open-Angle Glaucoma","volume":"126","author":"Chauhan","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.01.019_bib35","series-title":"Preferred Practice Pattern. Primary open-angle glaucoma","author":"American Academy of Ophthalmology","year":"2010"},{"key":"10.1016\/j.ophtha.2016.01.019_bib36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bjo.85.8.983","article-title":"Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension","volume":"85","author":"Zhang","year":"2001","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T11:04:39Z","timestamp":1748775879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0161642016000646"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.019","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Academy of Ophthalmology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}